Soleno Therapeutics, Inc. (SLNO) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	285.0M	190.4M	—	—	—
Cost of Revenue	3.9M	2.7M	—	—	—
Gross Profit	281.1M	187.7M	—	—	—
Operating Expenses
R&D Expense	38.4M	40.6M	78.6M	25.2M	15.3M
SG&A Expense	153.2M	132.1M	105.9M	13.5M	9.8M
General & Admin Expense	28.2M	—	105.9M	13.5M	9.8M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	1.7M	—	3.2M	2.7M	(712.0K)
Total Operating Expenses	193.3M	172.8M	187.7M	41.4M	24.4M
Cost and Expenses	197.2M	175.5M	187.7M	41.4M	24.4M
Operating Income (EBIT)	87.8M	14.9M	(187.7M)	(41.4M)	(24.4M)
Non-Operating
Interest Income	18.5M	17.0M	12.1M	2.6M	300.0K
Interest Expense	5.4M	5.5M	231.0K	—	—
Net Interest Income	13.1M	11.5M	11.8M	2.6M	300.0K
Other Non-Op Income/Expense	11.8M	5.9M	11.8M	2.4M	330.0K
Non-Operating Income (excl Interest)	(12.8M)	(11.4M)	(12.1M)	(2.4M)	(330.0K)
EBT (Pre-Tax Income)	99.6M	20.9M	(175.8M)	(39.0M)	(24.1M)
Income Tax Expense	3.5M	—	—	—	—
Bottom Line
Net Income	96.0M	20.9M	(175.8M)	(39.0M)	(24.1M)
Earnings from Cont. Ops	96.0M	20.9M	(175.8M)	(39.0M)	(24.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	95.6M	20.5M	(175.8M)	(39.0M)	(24.1M)
Per Share
Basic EPS	$1.96	$0.41	($4.38)	($2.36)	($2.87)
Diluted EPS	$1.77	$0.39	($4.38)	($2.36)	($2.87)
Revenue Per Share	$5.47	$3.58	$0.00	$0.00	$0.00
Shares
Basic Shares Outstanding	52.1M	53.2M	40.2M	16.5M	8.4M
Diluted Shares Outstanding	53.1M	54.3M	40.2M	16.5M	8.4M
Profitability Metrics
EBITDA	102.6M	28.4M	(173.6M)	(37.0M)	(22.1M)
D&A	2.0M	2.0M	2.0M	2.0M	2.0M
EBIT	100.5M	26.4M	(175.6M)	(39.0M)	(24.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026